Zacks Investment Research on MSN2h
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...
Medscape14h
FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors
Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.
Managed Healthcare Executive1d
FDA Approves Cabometyx to Treat Advanced Pancreatic Cancer
Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.
The American Journal of Managed Care1d
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...
Fierce Pharma1d
To approve Exelixis' Cabometyx in neuroendocrine tumors, FDA recognizes 'crossover impact' on survival
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. | ...